Expert Insights

How to prevent muscle loss on Wegovy

Sword Editorial Team

Footnotes

1

Neeland IJ, Linge J, Birkenfeld A, et al. Changes in lean body mass with glucagon-like peptide-1–based therapies and mitigation strategies. Diabetes Obes Metab. 2024;24(Suppl 4):16-27. https://pubmed.ncbi.nlm.nih.gov/38937282/

2

Johnson B, Milstead M, Thomas O, et al. Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonists: a cross-sectional study. Front Nutr. 2025. https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2025.1566498/full

3

Nauck MA. GLP 1 receptor agonists and lean body mass. Lancet Diabetes Endocrinol. 2024.https://www.thelancet.com/journals/landia/article/PIIS2213-8587(24)00272-9

4

Wilding JPH, Batterham RL, Calanna S, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. https://pubmed.ncbi.nlm.nih.gov/35441470/

5

Sword Health. Move ROI Whitepaper: Proactive MSK care delivers 3:1 ROI. 2025.https://swordhealth.com/reports-and-guides/sword-move-roi-whitepape

Portugal 2020Norte 2020European UnionPlano de Recuperação e ResiliênciaRepública PortuguesaNext Generation EU